In the narrow lanes of Kolkata's boroughs, government fever clinics see a surge of patients every monsoon. Suspected dengue cases arrive with high fever, body ache, and a plea for relief. What they receive is almost always paracetamol, sometimes oral rehydration salts, and a referral slip for a private lab. The platelet count that national guidelines say should guide their care is rarely done on-site.

Paracetamol and Panic: What Kolkata’s Dengue Clinics Actually Offer

The clinics, run by the Kolkata Municipal Corporation, are designed for triage. In peak season, a single clinic may see 40 to 80 suspected dengue patients daily. Staff check temperature, assess for warning signs like abdominal pain or vomiting, and dispense paracetamol for fever. Intravenous fluids are available for those who appear dehydrated, but the standard of care stops there.

Platelet counts, which the World Health Organization and India's national protocol recommend every 24 to 48 hours for confirmed dengue, are not performed in these clinics. The machines are absent, the reagents are not stocked, and the technicians are not trained. When a patient needs a complete blood count, the clinic hands them a referral to a private diagnostic chain like Dr. Lal PathLabs or a nursing home lab.

“We do what we can with what we have,” said Dr. Sunita Mukherjee, a senior physician at a borough clinic who agreed to speak on the condition that her name be used only for this quote. “Paracetamol brings down the fever. But we know we are missing the early signs of plasma leakage. We just don't have the equipment.”

The result is a system that manages symptoms but not the disease trajectory. Patients who might have been monitored as outpatients often return days later in shock, requiring hospital admission. The gap between what is stocked and what is needed defines dengue care in Kolkata's public sector.

The National Protocol That Exists on Paper

India's National Vector Borne Disease Control Programme (NVBDCP) has clear guidelines for dengue management. For confirmed cases, the protocol recommends a platelet count and hematocrit measurement every 24 to 48 hours until the patient is afebrile for 48 hours without antipyretics. Warning signs such as mucosal bleed, plasma leakage, or a rapid drop in platelet count trigger immediate referral to a higher-level facility.

The WHO's 2023 dengue classification, which India adopted, divides cases into dengue without warning signs, dengue with warning signs, and severe dengue. Monitoring platelets is central to the classification because a falling count often precedes plasma leakage, the main driver of severe disease. The policy is sound; the implementation is not.

In Kolkata, the gap is not a secret. A 2024 study in PLoS Neglected Tropical Diseases from Delhi found that daily platelet monitoring reduced the incidence of severe dengue by roughly 30% compared to symptom-based care alone. Similar findings have been reported from Colombo and Dhaka. Yet in Kolkata's municipal clinics, the protocol remains aspirational.

“The guidelines are there, but the operational reality is different,” said Dr. Suman Roy, a public health researcher at the Indian Institute of Public Health in Bhubaneswar, who has studied dengue surveillance in West Bengal. “Clinics are understaffed, underfunded, and the patient load is enormous. The system prioritizes the most urgent cases, but monitoring is not seen as urgent.”

Kolkata's case fatality rate for dengue hovers around 1.5%, according to municipal data. That is not high by global standards, but it represents preventable deaths. In hospitals that do monitor platelets, the case fatality rate is often lower. The difference is the count that was never done.

Why Clinics Skip the Count: Cost, Training, and Supply

The reasons are not mysterious. A basic hematology analyzer capable of platelet counts costs roughly US$ 3,000 to 5,000. Reagents, quality control materials, and a trained technician add recurring costs that municipal budgets do not cover. In a city where the health department's allocation for dengue is already stretched to cover fogging, bed nets, and public awareness campaigns, a machine for each clinic seems a luxury. Training is another barrier. Platelet counts require venipuncture, sample processing, and interpretation of results. Many clinic staff are nurses or paramedics trained in symptom triage, not laboratory science. Adding a lab service would require either hiring new staff or retraining existing ones, both of which take time and money that are not available. Supply chains are fragile. Even when clinics have had analyzers in the past—some donated by NGOs or corporate social responsibility programs—reagents often run out or expire. Without a steady supply, the machine sits idle. “We had a machine for a few months,” a former municipal health officer recalled. “But the reagent supplier stopped delivering because the payment was delayed. The machine is now in storage.”

Patients, for their part, are not demanding platelet counts. They come for fever relief. Paracetamol is expected; a blood test is an added expense and inconvenience. The clinic refers them, but many do not go. A 2023 survey by the Kolkata-based NGO Public Health Foundation found that fewer than 40% of patients referred for a CBC from a municipal clinic actually completed the test within 48 hours.

“We know we need to do better,” said Dr. Priya Banerjee, a consultant with the West Bengal health department who works on dengue control. “But the gap is not just equipment. It's a mindset. The system is designed to treat crisis, not to prevent it. Monitoring is prevention, and prevention is not prioritized.”

Evidence That Early Monitoring Cuts Severe Cases

The evidence that early platelet monitoring reduces severe dengue is robust. The 2024 study in PLoS Neglected Tropical Diseases followed 1,200 confirmed dengue patients across four Delhi hospitals. Half received standard care; half had daily platelet and hematocrit monitoring, with clinical action taken if counts dropped below 100,000 per microliter or fell by more than 20% in 24 hours. The monitored group had a 30% lower rate of severe dengue—defined by plasma leakage, shock, or organ impairment—and a 25% shorter hospital stay when admission was needed. Similar results emerged from a 2022 study in Colombo, Sri Lanka, where a mobile phone-based monitoring system tracked platelet counts and sent alerts to clinicians. The intervention reduced severe dengue by 22% and cut hospitalization costs by roughly 15%. In Dhaka, Bangladesh, a 2023 randomized trial found that home-based monitoring with a portable analyzer reduced hospital admissions for dengue by 18%.

The WHO recommends platelet monitoring as part of dengue clinical management, particularly in settings where dengue is endemic and healthcare resources are limited. The recommendation is based on moderate-quality evidence, but the organization acknowledges that implementation is uneven. “The science is clear,” said Dr. Rajesh Kumar, a virologist at the National Institute of Virology in Pune, who has studied dengue pathogenesis. “A falling platelet count is one of the earliest indicators of plasma leakage. If you catch it early, you can intervene with IV fluids and prevent progression to shock. The question is how to make monitoring accessible.”

Kolkata's case fatality rate of 1.5% is not alarming, but it is higher than in hospitals that monitor. At the Calcutta Medical College Hospital, where platelets are checked routinely, the case fatality rate for dengue in 2025 was 0.8%. The difference may be modest in absolute terms, but for the roughly 5,000 dengue cases reported annually in Kolkata, it represents dozens of lives. And the gap is likely wider among the poor, who rely on municipal clinics and cannot afford private labs.

The Private Sector Fills the Gap—Unevenly

Private diagnostic chains have stepped into the void. Dr. Lal PathLabs, SRL Diagnostics, and local nursing homes offer platelet counts for roughly INR 150 to 300 (US$ 1.80 to 3.60). Some offer home collection for a small additional fee. For a middle-class family, that is affordable. For a daily wage earner in a slum, it is not.

The result is a two-tier system. Patients who can pay get monitored; those who cannot rely on clinical judgment alone. In the bustees of central Kolkata, where families live in cramped rooms without running water, a INR 200 test is a significant expense. Many skip it, hoping the fever will pass. When it does not, they arrive at the hospital in shock, needing intensive care that costs ten times as much.

“We see this every monsoon,” said Dr. Ananya Das, an emergency physician at a private hospital in south Kolkata. “Patients come in with a history of fever for four or five days, and they haven't had a single blood test. Their platelet count is 20,000. They are bleeding from the gums. We stabilize them, but they could have been managed on an outpatient basis if someone had checked earlier.”

Municipal clinics refer patients for platelet counts only when warning signs appear—a policy that is consistent with national guidelines but misses the opportunity for early detection. The guidelines say that patients without warning signs can be managed at home, but they also recommend a baseline platelet count. In practice, the baseline is rarely done.

“The referral system is broken,” said Dr. Banerjee. “We tell patients to go to a lab, but we don't follow up. We don't know if they went. We don't have the data. It's a black box.”

The inequity is stark. A 2025 analysis by the Kolkata-based nonprofit Equitable Health Access found that residents of the city's wealthier wards were three times more likely to have a platelet count recorded during a dengue episode than residents of the poorest wards. The same study estimated that delayed detection of plasma leakage accounted for roughly 40% of dengue hospitalizations in the city, many of which could have been avoided.

A Low-Cost Fix That Could Scale

There is a potential solution, and it comes from Bihar. In 2024, the Bihar government piloted a program using portable hemoglobin-hematocrit analyzers in primary health centers in dengue-endemic districts. The devices, which cost roughly US$ 200 each, are about the size of a smartphone and run on rechargeable batteries. They measure hemoglobin and hematocrit from a finger-prick sample and give results in two minutes. While they do not measure platelets directly, hematocrit is a proxy for plasma leakage, and a rising hematocrit with a falling platelet count is a classic warning sign.

The pilot trained village health workers to use the devices and to interpret results using a simple algorithm. If the hematocrit rose by more than 20% from baseline, the patient was referred to a higher facility. In the first six months, the program reduced hospital admissions for dengue by roughly 15% in the pilot districts, according to preliminary data shared by the Bihar health department.

The Kolkata Municipal Corporation is watching. In early 2026, the corporation announced plans to explore a similar model for the 2027 dengue season. The proposal would place portable analyzers in each of the city's 16 borough clinics and train existing nursing staff to use them. The estimated cost is roughly US$ 50,000 for devices and training, a fraction of what the city spends on dengue hospitalization each year.

Donor interest is there. The Gates Foundation and USAID have both expressed interest in funding portable diagnostics for dengue in India, according to officials familiar with the discussions. But the money has not yet been committed, and the corporation's budget for 2026–27 does not include the devices.

“The Bihar model is promising, but it's not a silver bullet,” said Dr. Roy. “You need a reliable supply of test strips, a system for data collection, and a way to ensure that patients who are referred actually get to a hospital. The infrastructure is not just the device; it's the whole chain.”

The experience of Indian public health centres with zinc for diarrhea—stocked but often not prescribed—serves as a caution. Technology alone does not change practice. Training, supervision, and incentives matter.

What the Gap Costs Patients and the System

The cost of delayed detection is measurable. A patient with severe dengue typically spends 5 to 7 days in the hospital, often in an intensive care unit. The out-of-pocket cost for the family ranges from INR 10,000 to 30,000 (US$ 120 to 360), depending on the facility. For a family earning INR 10,000 a month, that is catastrophic. Many borrow money, sell assets, or skip treatment altogether.

For the health system, each case of severe dengue that could have been managed as an outpatient represents a wasted resource. Tertiary hospitals in Kolkata, such as the Calcutta Medical College Hospital and the Institute of Post Graduate Medical Education and Research, are overwhelmed during the monsoon. Beds are scarce, staff are stretched, and the cost of treating a severe dengue patient is roughly five times that of managing a mild case.

“We are treating the consequences of a failure to monitor,” said Dr. Das. “If we could catch plasma leakage early, we could keep patients out of the hospital. That would save money and beds for other emergencies.”

The human cost is harder to quantify. Every death from dengue is a tragedy, but the ones that follow a missed warning sign are particularly bitter. In a 2025 audit of dengue deaths in Kolkata, conducted by the West Bengal health department, roughly 30% were judged to have been potentially preventable with earlier detection of plasma leakage. The families of those patients had visited a municipal clinic, received paracetamol, and been sent home without a platelet count.

The gap is not unique to Kolkata. Similar stories play out in public clinics across India, where protocols exist on paper but are not followed. But Kolkata's size and density make the gap especially visible—and especially costly.

“Dengue is not going away,” said Dr. Banerjee. “It's endemic. We have to learn to live with it, and that means managing it as a chronic threat, not a crisis. Monitoring is the first step.”

The solution is not complex. A portable analyzer, a trained worker, and a referral system can change the trajectory of the disease. The question is whether the political will and the funding will arrive in time for the next monsoon.

In the clinics, the paracetamol bottles are restocked every week. The question remains: will the city's health department commit the funds and training needed to equip each borough clinic with a portable analyzer before the next surge, or will another monsoon season pass with patients being sent home without the monitoring that could save their lives?